March 2018 Newsletter

March 22, 2018:

APAO Showcases Artificial Intelligence, Regenerative Medicine at 2018 Congress

Myopia remained a top concern for attendees.

March 22, 2018:

US Ophthalmic Surgical Volume Shows Strong Growth in Q4-2017

Refractive procedures jumped 20 percent over Q4-2016.

March 22, 2018:

Ophthalmic Revenues Increase 7.0 Percent in Fourth Quarter

Companies posted revenues totaling $7.9 billion.

March 22, 2018:

ViewPoint Raises $35 Million for Topical Treatment Candidate for Cataracts, Presbyopia

Other companies raised $115 million, bringing the total for the past month to $150 million.

March 22, 2018:

Market Report: Patient Demand for Better Vision Will Drive Double-Digit Growth in IOL Revenues

The segment is expected to top $6.1 billion by 2023.

March 22, 2018:

Futures Forum Shines Spotlight on Innovation in Asia

The meeting featured presentations from several China- and Hong Kong-based ophthalmic start-ups, along with US, Israeli, and European firms.

March 22, 2018:

Shanghai Aier Eye Hospital Leads Evolution in Private Eye Care in China

The chain has 220 hospitals in mainland China, plus 88 in other countries, including the US.

March 22, 2018:

Epidemic of Diabetes in Shanghai Leads to Increase in DR Screening

A health survey conducted in 2014 revealed that 17.6 percent of the city’s 24 million residents have diabetes.

March 22, 2018:

China’s FDA to Merge into Broader Market Supervision Agency

Under the reorganization plan, local governments would oversee post-approval marketing.

March 22, 2018:

Preview of the 2018 ASCRS Meeting: What to Expect in Washington

No Tesla will be given away this year, ending a promotional event that started in 2015.

March 22, 2018:

Meet with Market Scope at the 2018 ASCRS Meeting

March 22, 2018:

Taiwan Liposome Company Registers for $50M IPO; Drug Firm Developing Treatment for ME due to RVO

The company’s platform is based on lipid-assembled drug delivery.

March 22, 2018:

Eylea Gains Approval in China for DME-Related Visual Impairment

This is the first indication for Eylea in China.

March 22, 2018:

Aerie Plans to Launch Rhopressa in Q2-2018, Expects 2018 Revenues of $20M to $30M

The glaucoma treatment gained US FDA approval in December 2017.

March 22, 2018:

Avedro, FDA Agree on Design, Size of First Pivotal Phase III Trial for Epi-on Cross-Linking

The company's US approved procedure for progressive keratoconus is an epi-off procedure.

March 22, 2018:

US Patent Board Allows Mylan’s Challenge to Restasis Patents to Move Forward

Allergan has been paring costs to prepare for the launch of a generic version of Restasis in 2018.

March 22, 2018:

Iridex Issues Recall of TruFocus LIO Premiere Laser Indirect Ophthalmoscope

The company said the recall impacted 2017 revenues.

March 22, 2018:

Bar-Ilan University Developing Nano-Drop for Refractive Error

Developers say the eye drops are designed to work with a laser source to apply a pattern to the superficial layer of the corneal epithelium to change the refractive index.

March 22, 2018:

Market Scope Weekly Poll

March 22, 2018:

March 2018 News Briefs

Social media